


## Viral Epidemiology Snapshot: February 27-March 5, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

<u>Co</u>				
<u>Virus</u>	<u>#Tested</u>	<u>#Positive</u>	<u>% Positive</u>	<u>Virus</u>
Flu A	431	67	15.5%	Adenovirus
Flu B	431	1	0.2%	Coronavirus
RSV	278	2	0.7%	Coronavirus
CoV-2 PUI	1073	32	3.0%	Coronavirus
CoV-2 Surveillance	471	5	1.1%	Coronavirus

Flu A Subtyping				
2009 H1N1	0			
Seasonal H1	0			
Seasonal H3	22			
No Subtype	45			
Pending subtype	0			

Other Respiratory Viruses					
<u>Virus</u>	<u>#Tested</u>	<u>#Positive</u>	<u>% Positive</u>		
Adenovirus	277	29	10.5%		
Coronavirus 229E	277	8	2.9%		
Coronavirus HKU1	277	0	0.0%		
Coronavirus NL63	277	5	1.8%		
Coronavirus OC43	277	14	5.1%		
Metapneumovirus	277	19	6.9%		
Rhinovirus/Enterovirus	277	70	25.3%		
Parainfluenza 1	277	0	0.0%		
Parainfluenza 2	277	0	0.0%		
Parainfluenza 3	277	4	1.4%		
Parainfluenza 4	277	0	0.0%		



**CoV-2 Positivity Rate Trends** 35.0% 4000 week 3500 30.0% Positivity Rate (%) 3000 25.0% per 2500 20.0% 2000 CoV-2 tests 15.0% 1500 10.0% 1000 5.0% 500 0.0% 0 Jan. Jan. Jan. Jan. Feb. Feb. Feb. Feb. 9 16 23 30 6 13 20 27 #CoV-2 Tests 3466 2313 2072 1495 1694 1544 1517 1542 PUI % + 32.9% 31.0% 22.8% 15.3% 10.4% 8.0% 4.0% 3.0% Surv. % + 9.4% 9.0% 6.2% 3.6% 3.2% 2.9% 0.7% 1.1% Week Starting

This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza (as of 11/14) and SARS-CoV-2 (as of 2/20) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

